Blueprint Medicines stock is trading -16.72% below its average target price of $126.05 after dropping -4.2% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $81.0 to $167.0 per share.
The stock has an above average percentage of its shares sold short at 9.1%, and a short ratio of 6.49. Since 1.27% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 104.5% of Blueprint Medicines's shares being owned by this investor type.
Institutions Invested in Blueprint Medicines
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 11% | 7,119,049 | $747,357,787 |
| 2024-09-30 | Vanguard Group Inc | 11% | 6,683,434 | $701,626,923 |
| 2024-09-30 | Price (T.Rowe) Associates Inc | 8% | 5,387,267 | $565,555,307 |
| 2024-09-30 | FMR, LLC | 7% | 4,516,771 | $474,170,634 |
| 2024-09-30 | Wellington Management Group, LLP | 6% | 3,964,610 | $416,204,771 |
| 2024-09-30 | State Street Corporation | 4% | 2,765,702 | $290,343,405 |
| 2024-09-30 | William Blair Investment Management, LLC | 3% | 1,674,799 | $175,820,404 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 1,480,187 | $155,390,036 |
| 2024-09-30 | Macquarie Group Limited | 2% | 1,263,661 | $132,659,136 |
| 2024-09-30 | JP Morgan Chase & Company | 2% | 1,222,052 | $128,291,023 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Blueprint Medicines.
